Showing results (351-360 of 407) with videos related to

Sort By:
Pageof 41
Cancer Research|May 19, 2017
NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast CancerHanan S Elsarraj, Kelli E Valdez, Yan Hong, et al.
Cell Reports|July 14, 2015
Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 ActivationZe-Yi Zheng, Lin Tian, Wen Bu, et al.
Elife|January 2, 2014
Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancySvasti Haricharan, Jie Dong, Sarah Hein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2019
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast CancerMothaffar F Rimawi, Polly Niravath, Tao Wang, et al.
Oncogene|October 19, 2022
STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potentialMeng Lin, Amy T Ku, Jie Dong, et al.
Molecular Cancer Research : MCR|March 12, 2016
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes ResistanceLuca Malorni, Mario Giuliano, Ilenia Migliaccio, et al.
Cancer Research|June 8, 2021
A Wnt-Independent LGR4-EGFR Signaling Axis in Cancer MetastasisFei Yue, Weiyu Jiang, Amy T Ku, et al.
Cancer Research|September 28, 2016
Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical OutcomesAndriy Marusyk, Doris P Tabassum, Michalina Janiszewska, et al.
NPJ Breast Cancer|May 28, 2021
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft modelsJamunarani Veeraraghavan, Carolina Gutierrez, Vidyalakshmi Sethunath, et al.
The Lancet. Oncology|March 28, 2024
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 studyBenjamin L Musher, Eric K Rowinsky, Brandon G Smaglo, et al.
Pageof 41